How India Exports Warfarin to the World

In the United States, warfarin is approved under multiple Abbreviated New Drug Applications (ANDAs), as listed in the FDA's Orange Book. The regulatory pathway for warfarin involves demonstrating bioequivalence to the reference listed drug, ensuring compliance with Current Good Manufacturing Practices (cGMP), and adhering to labeling requirements. Given that 38.6% of India's warfarin exports are directed to the U.S., Indian manufacturers must maintain rigorous quality standards to meet FDA expectations.

In the European Union, marketing authorization for warfarin is granted by the European Medicines Agency (EMA) or national competent authorities, depending on the chosen regulatory procedure. The United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA) oversees warfarin approvals post-Brexit. Both EMA and MHRA require compliance with EU Good Manufacturing Practice (GMP) guidelines, ensuring product quality and safety. Indian exporters targeting these markets must align with these stringent regulatory standards.

Warfarin is included in the 24th edition of the WHO Model List of Essential Medicines, published in September 2025. This inclusion underscores its critical role in global health for managing thromboembolic conditions. Compliance with international pharmacopoeia standards, such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), is essential for ensuring warfarin's quality and efficacy across different markets.

In India, warfarin is classified under Schedule H of the Drugs and Cosmetics Act, indicating it is a prescription-only medication. The National Pharmaceutical Pricing Authority (NPPA) regulates its pricing to ensure affordability. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC), ensuring compliance with national export regulations.

Warfarin's primary patents have expired, leading to a competitive generic market. This patent expiration allows multiple manufacturers to produce and export warfarin, contributing to its widespread availability and affordability globally.

In May 2025, the WHO Expert Committee on Selection and Use of Essential Medicines convened to update the Model List, reaffirming warfarin's inclusion due to its continued relevance in treating thromboembolic disorders. This decision highlights the ongoing global reliance on warfarin for anticoagulation therapy.

In January 2026, the WHO published a fact sheet emphasizing the importance of essential medicines, including warfarin, in addressing priority health-care needs. The document underscores the necessity for these medicines to be available, affordable, and of assured quality at all times. (who.int)

These developments reflect the sustained global demand for warfarin and the critical role of Indian manufacturers in meeting this need through adherence to international regulatory standards and quality assurance practices.

India's pharmaceutical industry, including the production of Warfarin, heavily relies on Active Pharmaceutical Ingredients (APIs) and Key Starting Materials (KSMs) imported from China. Approximately 70% of India's API requirements are fulfilled by Chinese suppliers. This dependency poses significant risks, as any disruption in Chinese supply chains can directly impact Indian pharmaceutical manufacturing.

In response, the Indian government has initiated the Production Linked Incentive (PLI) scheme to bolster domestic API and KSM production. In October 2024, two greenfield plants were inaugurated under this scheme to manufacture critical molecules like Penicillin G and Clavulanic Acid, aiming to reduce import dependence by half. However, the effectiveness of these measures in mitigating supply chain risks remains to be fully realized.

Our proprietary trade data indicates a high supplier concentration in Warfarin exports from India. The top five exporters account for 81.2% of the total export value, with AMNEAL PHARMACEUTICALS PRIVATE LIMITED alone contributing 38.6%. Such concentration increases the risk of supply disruptions if any of these key suppliers face operational challenges.

The PLI scheme, launched in 2020, aims to diversify the supplier base by incentivizing new entrants into API and KSM manufacturing. While this initiative has led to the establishment of new manufacturing units, the market remains dominated by a few large players, indicating that further efforts are needed to achieve a more balanced supplier landscape.

Recent geopolitical events have significantly impacted global supply chains. In February 2026, the closure of the Strait of Hormuz due to escalating conflicts disrupted the movement of oil and other critical goods, including pharmaceuticals. This led to increased shipping costs and delays, affecting the timely export of Warfarin from India.

Additionally, tensions in the Red Sea and the Suez Canal have forced shipping companies to reroute vessels around the Cape of Good Hope, further exacerbating delays and costs. The U.S. Food and Drug Administration (FDA) has acknowledged these disruptions, emphasizing the need for resilient supply chains to prevent drug shortages.

To address the identified risks, the following actionable steps are recommended:

• Diversify API and KSM Sources: Encourage the development of alternative domestic and international suppliers to reduce dependency on Chinese imports.

• Enhance Supplier Due Diligence: Implement rigorous assessment protocols for existing and potential suppliers to ensure reliability and compliance with quality standards.

• Invest in Infrastructure: Support the expansion of domestic manufacturing capabilities through financial incentives and infrastructure development to attract new entrants into the API and KSM market.

• Strengthen Logistics Planning: Develop contingency plans for shipping routes and logistics to mitigate the impact of geopolitical disruptions on export timelines.

• Monitor Regulatory Compliance: Regularly review and ensure compliance with international regulatory standards to maintain market access and prevent potential export bans.

RISK_LEVEL: MEDIUM